3 assets in Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant

Therapeutic assets addressing Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cabozantinib Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant	National Cancer Institute (NCI)	P2	B (60)
Nivolumab Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant	National Cancer Institute (NCI)	P2	B (60)
Ipilimumab Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant	National Cancer Institute (NCI)	P2	B (59)